DeepMed Research

National Heart, Lung, and Blood Institute

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease

Phase 1

Completed

Conditions: Sickle Cell Disease

Interventions: Drug: Hydroxyurea

First Posted Date: 2014-08-26

Last Posted Date: 2019-08-06

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 10

Registration Number: NCT02225132

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

Phase 2

Completed

Conditions: Acute Leukemia
Chronic Myelogenous Leukemia
Myelodysplasia
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Lymphoma, Large B-Cell, Diffuse
Lymphoma, B-Cell
Lymphoma, Follicular
Hodgkin's Lymphoma

Interventions: Drug: Tacrolimus (ARM with Methotrexate)
Drug: Tacrolimus (ARM with MMF and Cyclophosphamide)
Drug: Methotrexate (ARM with Maraviroc)
Drug: Methotrexate (ARM with Bortezomib)
Drug: Mycophenolate mofetil
Drug: Bortezomib
Drug: Maraviroc
Drug: Cyclophosphamide

First Posted Date: 2014-08-04

Last Posted Date: 2019-01-23

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 279

Registration Number: NCT02208037

Locations: 🇺🇸
University of Florida College of Medicine (Shands), Gainesville, Florida, United States
🇺🇸
Virginia Commonwealth University MCV Hospitals, Richmond, Virginia, United States
🇺🇸
University of North Carolina Hospital at Chapel Hill, Chapel Hill, North Carolina, United States

and more 27 locations

Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders

Terminated

Conditions: Lymphangiectasia
Lymphedema
Lymphangiomatosis
Pulmonary Lymphangiectasia

First Posted Date: 2014-06-05

Last Posted Date: 2024-04-11

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 14

Registration Number: NCT02156115

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Effect of Fasting on the NLRP3 Inflammasome

Completed

Conditions: Cardiovascular Disease
Inflammatory Disease

First Posted Date: 2014-04-24

Last Posted Date: 2021-02-01

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 23

Registration Number: NCT02122575

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure

Phase 2

Active, not recruiting

Conditions: Sickle Cell Disease
Thalassemia
Stem Cell Transplantation
Graft vs Host Disease

Interventions: Drug: Alemtuzumab
Drug: Filgrastim
Drug: Sirolimus
Drug: Cyclophosphamide
Drug: Pentostatin
Procedure: Radiotherapy

First Posted Date: 2014-04-07

Last Posted Date: 2025-03-25

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 56

Registration Number: NCT02105766

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Hispanic Community Health Study / Study of Latinos

Active, not recruiting

Conditions: Cardiovascular Disease

First Posted Date: 2014-02-12

Last Posted Date: 2023-12-27

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 16400

Registration Number: NCT02060344

Locations: 🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease

Completed

Conditions: Lung Disease
Pulmonary Fibrosis

First Posted Date: 2014-02-05

Last Posted Date: 2022-06-01

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 7

Registration Number: NCT02055222

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Hydroxyurea in Pulmonary Arterial Hypertension

Early Phase 1

Withdrawn

Conditions: Pulmonary Hypertension

First Posted Date: 2013-09-25

Last Posted Date: 2019-12-16

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Registration Number: NCT01950585

Links Between Inflammation and Cardiometabolic Diseases

Completed

Conditions: Healthy Volunteer
Inflammation
Diabetes Mellitus
Cardiovascular Disease

Interventions: Drug: Fludeoxyglucose F18
Drug: 13N-amonia

First Posted Date: 2013-09-04

Last Posted Date: 2025-05-16

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 150

Registration Number: NCT01934660

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Medical Arm of the Interagency Registry for Mechanically Assisted Circulatory Support

Completed

Conditions: Systolic Heart Failure
Heart Failure

First Posted Date: 2013-08-30

Last Posted Date: 2018-12-06

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 171

Registration Number: NCT01932294

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States

and more 8 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy